Adipotide/FTTP

Adipotide, also known as FTTP (Fat Targeted Pro-apoptotic Peptide), is an experimental peptidomimetic designed to induce weight loss by specifically targeting the blood supply of white adipose tissue. Unlike traditional weight-loss compounds that focus on central nervous system pathways for appetite suppression, Adipotide utilizes a targeted “anti-angiogenic” approach. It consists of a homing domain that binds to receptors specifically expressed in the blood vessels that nourish fat cells, and a pro-apoptotic domain that triggers programmed cell death (apoptosis) in those vessels. By selectively destroying the vascular infrastructure of fat deposits, Adipotide causes the fat cells to atrophy and be reabsorbed by the body.

This mechanism makes Adipotide a highly unique subject of study in obesity research, particularly for targeting stubborn visceral fat that is often resistant to diet and exercise. Research has shown that Adipotide can lead to rapid reductions in body fat and significant improvements in insulin sensitivity by physically reducing the volume of adipose tissue rather than just altering caloric intake. Because it acts directly on the fat tissue’s supporting system, it offers a distinct metabolic profile. It remains a key compound in scientific investigations focused on adipose tissue biology, metabolic syndrome, and the potential for targeted vascular therapies to address severe obesity and its related health complications.